141 related articles for article (PubMed ID: 11830489)
1. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells.
Veuger MJ; Heemskerk MH; Honders MW; Willemze R; Barge RM
Blood; 2002 Feb; 99(4):1373-80. PubMed ID: 11830489
[TBL] [Abstract][Full Text] [Related]
2. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
Veuger MJ; Honders MW; Willemze R; Barge RM
Eur J Haematol; 2002 Sep; 69(3):171-8. PubMed ID: 12406011
[TBL] [Abstract][Full Text] [Related]
3. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia.
Veuger MJ; Honders MW; Landegent JE; Willemze R; Barge RM
Blood; 2000 Aug; 96(4):1517-24. PubMed ID: 10942400
[TBL] [Abstract][Full Text] [Related]
4. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity.
Stegmann AP; Honders WH; Willemze R; Ruiz van Haperen VW; Landegent JE
Blood; 1995 Mar; 85(5):1188-94. PubMed ID: 7532033
[TBL] [Abstract][Full Text] [Related]
5. A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells.
Veuger MJ; Honders MW; Landegent JE; Willemze R; Barge RM
Leukemia; 2000 Sep; 14(9):1678-84. PubMed ID: 10995016
[TBL] [Abstract][Full Text] [Related]
6. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
7. Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.
Jaramillo AC; Bergman AM; Comijn EM; Jansen G; Kaspers GJL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1346. PubMed ID: 32727269
[TBL] [Abstract][Full Text] [Related]
8. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Stegmann AP; Honders MW; Willemze R; Landegent JE
Leukemia; 1995 Jun; 9(6):1032-8. PubMed ID: 7541096
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Veuger MJ; Honders MW; Spoelder HE; Willemze R; Barge RM
Leuk Res; 2003 May; 27(5):445-53. PubMed ID: 12620296
[TBL] [Abstract][Full Text] [Related]
10. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Stegmann AP; Honders MW; Kester MG; Landegent JE; Willemze R
Leukemia; 1993 Jul; 7(7):1005-11. PubMed ID: 7686601
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
12. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
[TBL] [Abstract][Full Text] [Related]
13. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
Br J Haematol; 2000 Jul; 110(1):170-9. PubMed ID: 10930995
[TBL] [Abstract][Full Text] [Related]
14. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
15. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
Flasshove M; Strumberg D; Ayscue L; Mitchell BS; Tirier C; Heit W; Seeber S; Schütte J
Leukemia; 1994 May; 8(5):780-5. PubMed ID: 7514246
[TBL] [Abstract][Full Text] [Related]
17. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
18. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Hapke DM; Stegmann AP; Mitchell BS
Cancer Res; 1996 May; 56(10):2343-7. PubMed ID: 8625309
[TBL] [Abstract][Full Text] [Related]
19. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
